The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004.

BACKGROUND Trichomonas vaginalis infection is a common sexually transmitted protozoal infection and is associated with several adverse health outcomes, such as preterm birth, delivery of a low-birth weight infant, and facilitation of sexual transmission of human immunodeficiency virus. The annual incidence in the United States has been estimated to be 3-5 million cases. However, there are no data on the prevalence of trichomoniasis among all reproductive-age women. We estimated the prevalence of T. vaginalis infection from a nationally representative sample of women in the United States. METHODS Women aged 14-49 years who participated in the National Health and Examination Survey cycles for 2001-2004 provided self-collected vaginal swab specimens. The vaginal fluids extracted from these swabs were evaluated for the presence of T. vaginalis using polymerase chain reaction. RESULTS Overall, 3754 (81%) of 4646 women provided swab specimens. The prevalence of T. vaginalis infection was 3.1% (95% confidence interval [CI], 2.3%-4.3%); for non-Hispanic white women, it was 1.3% (95% CI, 0.7%-2.3%); for Mexican American women, it was 1.8% (95% CI, 0.9%-3.7%); and for non-Hispanic black women, it was 13.3% (95% CI, 10.0%-17.7%). Factors that remained associated with increased likelihood of T. vaginalis infection in multivariable analyses included non-Hispanic black race/ethnicity, being born in the United States, a greater number of lifetime sex partners, increasing age, lower educational level, poverty, and douching. CONCLUSIONS The prevalence of T. vaginalis infection among women in the United States was 3.1%. A significant racial disparity exists; the prevalence among non-Hispanic black women was 10.3 times higher than that among non-Hispanic white and Mexican American women. Optimal prevention and control strategies for T. vaginalis infection should be explored as a means of closing the racial disparity gaps and decreasing adverse health outcomes due to T. vaginalis infection.

[1]  Robert E. Johnson,et al.  Gonorrhea and Chlamydia in the United States among Persons 14 to 39 Years of Age, 1999 to 2002 , 2007, Annals of Internal Medicine.

[2]  C. Boyer,et al.  Sociodemographic markers and behavioral correlates of sexually transmitted infections in a nonclinical sample of adolescent and young adult women. , 2006, The Journal of infectious diseases.

[3]  J. French,et al.  Readily treatable reproductive tract infections and preterm birth among black women. , 2006, American journal of obstetrics and gynecology.

[4]  D. Popadic,et al.  Diagnosis of Trichomonas vaginalis infection: The sensitivities and specificities of microscopy, culture and PCR assay. , 2006, European journal of obstetrics, gynecology, and reproductive biology.

[5]  J. Fortenberry,et al.  Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. , 2005, The Journal of infectious diseases.

[6]  S. Garland,et al.  Comparison of conventional testing to polymerase chain reaction in detection of Trichomonas vaginalis in indigenous women living in remote areas , 2005, International journal of STD & AIDS.

[7]  M. Handcock,et al.  The Prevalence of Trichomoniasis in Young Adults in the United States , 2005, Sexually transmitted diseases.

[8]  W. Secor,et al.  Trichomonas vaginalis-Induced Epithelial Monolayer Disruption and Human Immunodeficiency Virus Type 1 (HIV-1) Replication: Implications for the Sexual Transmission of HIV-1 , 2005, Infection and Immunity.

[9]  R. Garfein,et al.  Prevalence and Correlates of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis infections, and Bacterial Vaginosis Among a Cohort of Young Injection Drug Users in Baltimore, Maryland , 2005, Sexually transmitted diseases.

[10]  Jill S. Huppert,et al.  Use of an Immunochromatographic Assay for Rapid Detection of Trichomonas vaginalis in Vaginal Specimens , 2005, Journal of Clinical Microbiology.

[11]  W. Miller,et al.  Targeted Screening for Trichomonas vaginalis with Culture Using a Two-Step Method in Women Presenting for STD Evaluation , 2004, Sexually transmitted diseases.

[12]  S. Pinkerton,et al.  Estimates of the Annual Number and Cost of New HIV Infections Among Women Attributable to Trichomoniasis in the United States , 2004, Sexually transmitted diseases.

[13]  B. Vuylsteke,et al.  Comparison of culture and different PCR assays for detection of Trichomonas vaginalis in self collected vaginal swab specimens , 2003, Sexually transmitted infections.

[14]  G. Burstein,et al.  Sexually transmitted diseases treatment guidelines , 2003, Current opinion in pediatrics.

[15]  E. Lara-Torre,et al.  Accuracy of detection of trichomonas vaginalis organisms on a liquid-based papanicolaou smear. , 2003, American journal of obstetrics and gynecology.

[16]  R. Crosby,et al.  Predictors of infection with Trichomonas vaginalis: a prospective study of low income African-American adolescent females , 2002, Sexually transmitted infections.

[17]  E. Erbelding,et al.  Trichomonas vaginalis polymerase chain reaction compared with standard diagnostic and therapeutic protocols for detection and treatment of vaginal trichomoniasis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  D. Smith,et al.  The diagnosis of chlamydia, gonorrhoea, and trichomonas infections by self obtained low vaginal swabs, in remote northern Australian clinical practice , 2002, Sexually transmitted infections.

[19]  W. Miller,et al.  Development and Validation of a PCR-Based Enzyme-Linked Immunosorbent Assay with Urine for Use in Clinical Research Settings To Detect Trichomonas vaginalis in Women , 2002, Journal of Clinical Microbiology.

[20]  P. Kerndt,et al.  Trichomonas vaginalis, HIV, and African-Americans. , 2001, Emerging infectious diseases.

[21]  M. Trucco,et al.  TaqMan-Based Detection of Trichomonas vaginalis DNA from Female Genital Specimens , 2001, Journal of Clinical Microbiology.

[22]  J. Schwebke,et al.  Evaluation of the Affirm Ambient Temperature Transport System for the Detection and Identification ofTrichomonas vaginalis, Gardnerella vaginalis, andCandida Species from Vaginal Fluid Specimens , 2001, Journal of Clinical Microbiology.

[23]  J. Schwebke,et al.  Detection of Trichomonosis in Vaginal and Urine Specimens from Women by Culture and PCR , 2000, Journal of Clinical Microbiology.

[24]  F. Behets,et al.  Trichomoniasis in pregnant human immunodeficiency virus-infected and human immunodeficiency virus-uninfected congolese women: prevalence, risk factors, and association with low birth weight. , 1999, American journal of obstetrics and gynecology.

[25]  Edward L. Korn,et al.  Analysis of Health Surveys , 1999 .

[26]  W. Cates,et al.  Estimates of the Incidence and Prevalence of Sexually Transmitted Diseases in the United States , 1999 .

[27]  D. Fleming,et al.  From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. , 1999, Sexually transmitted infections.

[28]  M. Krohn,et al.  Trichomonas vaginalis Associated With Low Birth Weight and Preterm Delivery , 1997, Sexually transmitted diseases.

[29]  G. Pugliese,et al.  Severe Streptococcus pyogenes Infections, United Kingdom, 2003–2004 , 2008, Emerging infectious diseases.

[30]  W. Miller,et al.  Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  B. Van Der Pol.  Trichomonas vaginalis infection: the most prevalent nonviral sexually transmitted infection receives the least public health attention. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  J. Stockman.  Gonorrhea and Chlamydia in the United States among Persons 14 to 39 Years of Age , 2007, Annals of Internal Medicine.

[33]  W. Miller,et al.  A Randomized, Double-Blind, Placebo-Controlled Trial of Combined Nevirapine and Zidovudine Compared with Nevirapine Alone in the Prevention of Perinatal Transmission of HIV in Zimbabwe , 2007 .

[34]  T. Davis,et al.  Clinical evaluation of affirm VPIII in the detection and identification of Trichomonas vaginalis, Gardnerella vaginalis, and Candida species in vaginitis/vaginosis. , 2004, Infectious diseases in obstetrics and gynecology.

[35]  Guoyu Tao,et al.  The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. , 2004, Perspectives on sexual and reproductive health.

[36]  Stuart Berman,et al.  Perspectives on Sexual and Reproductive Health Sexually Transmitted Diseases among American Youth: Incidence and Prevalence Estimates, 2000 , 2022 .

[37]  W. Levine,et al.  Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. , 1998, The Journal of infectious diseases.

[38]  P. Piot,et al.  Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. , 1993 .